David L. Johnson

Energy Systems Network (ESN) is a non-profit organization founded in 2009 that works with companies worldwide to accelerate the development and commercialization of energy and transportation technology. ESN is based in Indianapolis, IN, and is part of the Central Indiana Corporate Partnership (CICP). ESN conducts industry research, pilot projects, and collaborative convening to advance new technologies and solutions. The organization has worked with companies such as Cummins, Duke Energy, Delphi, Toyota, and Toshiba, among others, to showcase and advance new technologies. The CEO of ESN is Paul Mitchell.

The Central Indiana Corporate Partnership is a private company that focuses on human capital, entrepreneurship, innovation, and business climate. The company is based in Indianapolis, IN and has subsidiaries in the United States. The CEO of the company is Melina M. Kennedy.

BioCrossroads (BioCrossroads) is a venture capital firm founded in 2002. The firm is headquartered in Indianapolis, Indiana.

Bioscience Vaccines, Inc. develops a novel technology for the development of vaccine supplements. It engages in development of a vaccine adjuvant and companion products for infectious diseases. The firm also involves in the exploration of prevention and immunotherapeutic treatments for cancer using tissue vaccines. The company was founded by Anthony J. Hubbard and and Amy M. Overby in 2010 and is headquartered in West Lafayette, IN.

CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University.